PTPRC and hepatocellular carcinoma: More interestingly, the Hepa1-6 hepatoma model, which had a similar cytokines panel response to APG-1387 as ID8 (but without response to the combination of APG-1387 and anti-PD-1 antibody; Fig. 2F), there was no difference in proportions of CD45 + NK1.1 + cells in tumors between APG-1387 treatment and vehicle control (Fig. 3P).